EQS — News: FamiCord AG wins promising new client for its CDMO activities with manufacturing agreement for pivotal Phase II/III trial with initial value in the low single — digit millions of euros

EQS-News: FamiCord AG / Key word(s): Contract FamiCord AG wins promising new client for its CDMO activities with manufacturing agreement for pivotal Phase II/III trial with initial value in the low single-digit millions of euros 24.09.2026 / 12:28 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ FamiCord AG wins promising new client for its CDMO activities with manufacturing agreement for pivotal Phase II/III trial with initial value in the low single-digit millions of euros • FamiCord CDMO division selected by VERIGRAFT to establish the GMP manufacturing process for personalized tissue-engineered vein P-TEV at its Warsaw site • Approximately 18-month collaboration with an estimated contract value in the low single-digit millions of euros and the potential for further extension • Agreement adds pivotal Phase II/III program to FamiCord's CDMO activities; trial expected to begin Q1 2027 Leipzig, 24 September 2026 — FamiCord AG, Europe's leading cell bank and the third largest worldwide, today announced that its CDMO brand “Bramble Bio”, under which the Group aggregates its CDMO a